López-Roa Paula, Esteban Jaime, Muñoz-Egea María-Carmen
Department of Clinical Microbiology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, UAM, 28040 Madrid, Spain.
Microorganisms. 2022 Dec 29;11(1):90. doi: 10.3390/microorganisms11010090.
In recent years, has appeared as an emerging pathogen, with an increasing number of disease cases reported worldwide that mainly occur among patients with chronic lung diseases or impaired immune systems. The treatment of this pathogen represents a challenge due to the multi-drug-resistant nature of this species and its ability to evade most therapeutic approaches. However, although predisposing host factors for disease are well known, intrinsic pathogenicity mechanisms of this mycobacterium are still not elucidated. Like other mycobacteria, intracellular invasiveness and survival inside different cell lines are pathogenic factors related to the ability of to establish infection. Some of the molecular factors involved in this process are well-known and are present in the mycobacterial cell wall, such as trehalose-dimycolate and glycopeptidolipids. The ability to form biofilms is another pathogenic factor that is essential for the development of chronic disease and for promoting mycobacterial survival against the host immune system or different antibacterial treatments. This capability also seems to be related to glycopeptidolipids and other lipid molecules, and some studies have shown an intrinsic relationship between both pathogenic mechanisms. Antimicrobial resistance is also considered a mechanism of pathogenicity because it allows the mycobacterium to resist antimicrobial therapies and represents an advantage in polymicrobial biofilms. The recent description of hyperpathogenic strains with the potential interhuman transmission makes it necessary to increase our knowledge of pathogenic mechanisms of this species to design better therapeutic approaches to the management of these infections.
近年来,[某种病原体]作为一种新兴病原体出现,全球报告的病例数不断增加,主要发生在慢性肺部疾病患者或免疫系统受损的患者中。由于该菌种具有多重耐药性且能够逃避大多数治疗方法,对这种病原体的治疗构成了挑战。然而,尽管已知疾病的易感宿主因素,但这种分枝杆菌的内在致病机制仍未阐明。与其他分枝杆菌一样,在不同细胞系内的细胞内侵袭性和存活能力是与[该病原体]建立感染能力相关的致病因素。参与这一过程的一些分子因素是众所周知的,存在于分枝杆菌细胞壁中,如海藻糖二霉菌酸酯和糖肽脂。形成生物膜的能力是另一个致病因素,对于慢性病的发展以及促进分枝杆菌在宿主免疫系统或不同抗菌治疗下的存活至关重要。这种能力似乎也与糖肽脂和其他脂质分子有关,一些研究表明这两种致病机制之间存在内在联系。抗菌耐药性也被认为是一种致病机制,因为它使分枝杆菌能够抵抗抗菌治疗,并在多微生物生物膜中具有优势。最近对具有人际传播潜力的高致病性菌株的描述使得有必要增加我们对该菌种致病机制的了解,以便设计出更好的治疗方法来管理这些感染。